Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
James ND, Pirrie SJ, Pope AM, Barton D, Andronis L, Goranitis I, Collins S, Daunton A, McLaren D, O'Sullivan J, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown J, Chakraborti P, Hussain S, Russell M, Billingham LJ. James ND, et al. Among authors: pirrie sj. JAMA Oncol. 2016 Apr;2(4):493-9. doi: 10.1001/jamaoncol.2015.5570. JAMA Oncol. 2016. PMID: 26794729 Free article. Clinical Trial.
The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers.
Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, Morse J, Hull D, Patman G, Kagebayashi C, Hussain S, Graham J, Reeves H, Satomura S. Johnson PJ, et al. Among authors: pirrie sj. Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):144-53. doi: 10.1158/1055-9965.EPI-13-0870. Epub 2013 Nov 12. Cancer Epidemiol Biomarkers Prev. 2014. PMID: 24220911
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
Andronis L, Goranitis I, Pirrie S, Pope A, Barton D, Collins S, Daunton A, McLaren D, O'Sullivan JM, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown JE, Chakraborti P, Hussain SA, Russell JM, Billingham LJ, James ND. Andronis L, et al. BJU Int. 2017 Apr;119(4):522-529. doi: 10.1111/bju.13549. Epub 2016 Jul 10. BJU Int. 2017. PMID: 27256016 Free article. Clinical Trial.
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, Collins S, McLaren D, O'Sullivan J, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown J, Chakraborti P, Russell M, Billingham L. James N, et al. Health Technol Assess. 2016 Jul;20(53):1-288. doi: 10.3310/hta20530. Health Technol Assess. 2016. PMID: 27434595 Free PMC article. Clinical Trial.
Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial.
Rea D, Francis A, Wallis M, Thomas J, Bartlett J, Bowden S, Dodwell D, Fallowfield L, Gaunt C, Hanby A, Jenkins V, Matthews L, Pinder S, Pirrie S, Reed M, Wilcox M, Roberts T, Kirwan C, Brookes C, Fairbrother P, Billingham L, Evans A, Young J. Rea D, et al. Ann Surg Oncol. 2017 Dec;24(Suppl 3):566-567. doi: 10.1245/s10434-017-6174-y. Epub 2017 Nov 28. Ann Surg Oncol. 2017. PMID: 29185098 No abstract available.
36 results